Literature DB >> 29733073

At 50 years of the description of acute respiratory distress syndrome.

Raúl Carrillo-Esper1, Gilberto Felipe Vázquez-De Anda2, Cynthia Ivonne Mejía-Pérez2, María Guadalupe Delaye-Aguilar3, Ana Ivonne Pérez-Castañeda3, Jesús Carlos Briones-Garduño4, Manuel Antonio Díaz de León-Ponce1.   

Abstract

In 1967, Ashbaugh et al. published in the Lancet the description of a new entity, for which they coined the name "adult respiratory distress syndrome". On that article, they thoroughly described 12 patients who had respiratory distress with bilateral pulmonary infiltrates and oxygen therapy-refractory hypoxemia. For its management, emphasis was made on the importance of intubation and mechanical ventilation with positive end-expiratory pressure. At 50 years of its first publication, great advances on the knowledge of this condition have been achieved, which has influenced on patient management and survival. To celebrate this 50th anniversary, the National Academy of Medicine of Mexico organized a symposium with the purpose to spread the knowledge about this condition, recognize the researchers who made the original description and those who over the course of 50 years of history have contributed to its better understanding. The symposium addressed the topics of lung-kidney interaction, molecular bases of the disease and therapeutic advances. Copyright:
© 2018 Secretaría de Salud.

Entities:  

Keywords:  Acute respiratory distress syndrome; Hipoxemia; Hypoxemia; Mechanical ventilation; Positive end-expiratory pressure; Presión positiva al final de la espiración; Síndrome de insuficiencia respiratoria aguda; Ventilación mecánica

Mesh:

Year:  2018        PMID: 29733073     DOI: 10.24875/GMM.M18000062

Source DB:  PubMed          Journal:  Gac Med Mex        ISSN: 0016-3813            Impact factor:   0.302


  1 in total

1.  Serum interleukin-18: A novel prognostic indicator for acute respiratory distress syndrome.

Authors:  Guangsu Dong; Fei Wang; Liang Xu; Min Zhu; Bin Zhang; Bin Wang
Journal:  Medicine (Baltimore)       Date:  2019-05       Impact factor: 1.817

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.